Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and pharmacokinetics of calaspargase pegol in adults with newly diagnosed Philadelphia-negative ALL: A phase 2/3 study
    Meeting Abstract

    Stock, W.; Park, J. H.; Emadi, A.; Abdul-Hay, M.; Cassaday, R. D.; Pullarkat, V. A.; Webster, J.; Pandya, S. S.; Mogul, M. J.; Shvenke, Y.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Siremadlin (HDM201) is well tolerated and demonstrates clinical activity in patients with acute myeloid leukemia who have relapsed after allogeneic stem cell transplantation: A subset analysis of safety and preliminary efficacy
    Meeting Abstract

    Stein, E. M.; Chromik, J.; Carpio, C.; Mous, R.; Kiladjian, J. J.; Alatrash, G.; Curti, A.; Craddock, C.; Schmid, C.; Zeiser, R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Safety and efficacy of menin inhibition in patients (Pts) with MLL-rearranged and NPM1 mutant acute leukemia: A phase (Ph) 1, first-in-human study of SNDX-5613 (AUGMENT 101)
    Meeting Abstract

    Stein, E. M.; Aldoss, I.; DiPersio, J. F.; Stone, R. M.; Arellano, M. L.; Rosen, G.; Meyers, M. L.; Huang, Y. F.; Smith, S.; Bagley, R. G.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic highrisk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Evolve CLL/SLL study (SWOG S1925; NCT#04269902)
    Meeting Abstract

    Stephens, D. M.; Moseley, A.; Hill, B. T.; Pagel, J. M.; Shadman, M.; Fisch, M.; Danilov, A. V.; Ng, D.; Mato, A. R.; Brander, D. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Updated survival and response analyses from a phase 1 study of ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation
    Meeting Abstract

    Stein, E. M.; DiNardo, C. D.; Fathi, A. T.; Mims, A. S.; Savona, M. R.; Stein, A. S.; Stone, R. M.; Winer, E. S.; Seet, C. S.; Döhner, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies
    Meeting Abstract

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease(MRD)-driven, time-limited approach
    Meeting Abstract

    Roeker, L. E.; Leslie, L. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Pena-Velasquez, C.; Lebowitz, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Safety and efficacy of cusatuzumab in combination with venetoclax and azacitidine (CVA) in patients with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy; An open-label, multicenter, phase 1b study
    Meeting Abstract

    Roboz, G. J.; Pabst, T.; Aribi, A.; Brandwein, J. M.; Döhner, H.; Fiedler, W.; Gandini, D.; Geddes, M.; Hou, J. Z.; Howes, A. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Safety and efficacy of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: An updated analysis
    Meeting Abstract

    Przespolewski, A.; Goldberg, A. D.; Talati, C.; Fazal, S.; Vachhani, P.; Sanikommu, S. R. R.; Thota, S.; Waksal, J.; Ball, B.; Famulare, C.; more...
    Blood (2021)

    Fulltext@MSK | Save